Display options
Cite
Nagata T, Kanamori M, Sekine S, et al. Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer. Mol Clin Oncol. 2021;14(5):103doi: 10.3892/mco.2021.2265.
Nagata, T., Kanamori, M., Sekine, S., Arai, M., Moriyama, M., & Fujii, T. (2021). Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer. Molecular and clinical oncology, 14(5), 103. https://doi.org/10.3892/mco.2021.2265
Nagata, Takuya, et al. "Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer." Molecular and clinical oncology vol. 14,5 (2021): 103. doi: https://doi.org/10.3892/mco.2021.2265
Nagata T, Kanamori M, Sekine S, Arai M, Moriyama M, Fujii T. Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer. Mol Clin Oncol. 2021 May;14(5):103. doi: 10.3892/mco.2021.2265. Epub 2021 Mar 17. PMID: 33796292; PMCID: PMC8010507.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2021 May;14(5):103. doi: 10.3892/mco.2021.2265. Epub 2021 Mar 17.

Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer.

Molecular and clinical oncology

Takuya Nagata, Masahiko Kanamori, Shinichi Sekine, Mie Arai, Makoto Moriyama, Tsutomu Fujii

Affiliations

  1. Department of Surgery, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
  2. Department of Human Science, University of Toyama, Toyama 930-0194, Japan.
  3. Department of Surgery, Kamiichi General Hospital, Toyama 930-0391, Japan.
  4. Department of Surgery, Toyama Nishi General Hospital, Toyama 939-2716, Japan.
  5. Department of Surgery, Tomei Atsugi Hospital, Kanagawa 243-8571, Japan.
  6. Department of Science and Surgery, University of Toyama, Toyama 930-0194, Japan.

PMID: 33796292 PMCID: PMC8010507 DOI: 10.3892/mco.2021.2265

Abstract

Modulated electro-hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance-matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim of the present study was to report the outcomes of mEHT in the treatment of advanced breast cancer. mEHT was examined in 10 patients with advanced metastatic breast cancer and recurrent disease, who were considered incurable by standard therapy protocols. Of the 10 patients, partial response was achieved in 3, disease stability in 3, and progressive disease in 4; however, their quality of life was improved based on their subjective reports. No adverse effects were observed in any of the 10 patients. The present study demonstrated the feasibility of mEHT as a possible therapy for advanced breast cancer cases when standard therapies fail. Moreover, mEHT had no side effects and may be combined with various treatments for long-term therapy.

Copyright: © Nagata et al.

Keywords: breast cancer; chemotherapy; hyperthermia; irradiation

Conflict of interest statement

The authors declare that they have no competing interests.

References

  1. Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):731-44 - PubMed
  2. Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):371-80 - PubMed
  3. Nat Commun. 2019 Oct 25;10(1):4871 - PubMed
  4. Int J Hyperthermia. 1995 May-Jun;11(3):315-22 - PubMed
  5. Radiology. 1977 May;123(2):463-74 - PubMed
  6. Int J Hyperthermia. 2019 Nov;36(sup1):4-9 - PubMed
  7. Ochsner J. 2017 Winter;17(4):405-411 - PubMed
  8. Curr Opin Obstet Gynecol. 2002 Feb;14(1):45-52 - PubMed
  9. J Adv Res. 2020 Mar 17;24:175-182 - PubMed
  10. Int J Clin Oncol. 2007 Jun;12(3):192-8 - PubMed
  11. PLoS One. 2019 Jun 19;14(6):e0217894 - PubMed
  12. Integr Cancer Ther. 2019 Jan-Dec;18:1534735419878505 - PubMed
  13. Ann Surg Oncol. 2003 Apr;10(3):210-2 - PubMed
  14. Neoplasma. 2020 May;67(3):677-683 - PubMed
  15. Int J Mol Sci. 2020 Jul 19;21(14): - PubMed
  16. Med Dosim. 2016 Autumn;41(3):253-7 - PubMed
  17. Front Oncol. 2019 Nov 01;9:1012 - PubMed
  18. Radiother Oncol. 2013 Nov;109(2):194-9 - PubMed
  19. Nat Med. 2019 Apr;25(4):620-627 - PubMed
  20. Immunotherapy. 2015;7(8):855-60 - PubMed
  21. Int J Hyperthermia. 2019;36(1):499-510 - PubMed
  22. Indian J Pharmacol. 2011 May;43(3):236-45 - PubMed
  23. Korean J Intern Med. 2018 Mar;33(2):442-445 - PubMed
  24. Int J Hyperthermia. 1986 Apr-Jun;2(2):111-37 - PubMed
  25. J Clin Oncol. 2005 May 1;23(13):3079-85 - PubMed
  26. Front Oncol. 2020 Mar 24;10:376 - PubMed
  27. Cancer Res. 1984 Oct;44(10 Suppl):4721s-4730s - PubMed

Publication Types